Amgen, Biogen Idec, Inc. (Massachusetts) Leap into Generic Drug Market
Published: Jan 20, 2012
Biotechnology companies spent years lobbying against allowing generic versions of their expensive cutting-edge medicines, warning that copying complicated drugs made from living cells could put patients at risk and undermine innovators. But that was then. Bowing to the inevitability of low-cost competition as federal officials push to contain health care spending, biotechs are now scrambling to secure a piece of the discount market for themselves. And Massachusetts, known for its influential cluster of biotechnology companies, is at the center of the action.